Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer.

Luca AfferiChiara LonatiFrancesco MontorsiAlberto BrigantiAndrea NecchiAndrea MariAndrea MinerviniRiccardo CampiEttore di TrapaniOttavio de CobelliR Jeffrey KarnesMohamed AhmedM Carmen MirMaria Asuncion AlgarraMichael RinkStefania ZamboniClaudio SimeoneWojciech KrajewskiEvanguelos XylinasFrancesco SoriaKees HendricksenSarah EinerhandAgostino MatteiRoberto CarandoMathieu RoumiguiéAnne Sophie BajeotPeter C BlackShahrokh F ShariatMarco Moschininull null

Published in: World journal of urology (2022)

Carboplatin-based might not improve OS in patients with pN1-3 cM0 BCa. Our results underline the need for alternative therapies for cisplatin-ineligible patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
phase ii study
peritoneal dialysis
squamous cell carcinoma
clinical trial
patient reported outcomes
open label
placebo controlled